Clinical Trial

Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 21, 2022 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study aims to compare the efficacy and safety of reduced adjuvant XELOX treatment (4 cycles of XELOX followed by 4 cycles of capecitabine alone) to standard adjuvant XELOX treatment (8 cycles of XELOX).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-03-05.
Status change: Not Yet Recruiting → Recruiting 2022-02-04
Trial Details
NCT Number NCT04787354
Lead Sponsor Hallym University Medical Center
Conditions Gastric Cancer
Enrollment 976 participants
Start Date 2021-11-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2022-02-21